Adipotide (FTPP)
Also known as FTPP, Fat-Targeted Proapoptotic Peptide
Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide), is an experimental compound studied in animal models for its ability to induce localized apoptosis (programmed cell death) in the blood vessels supplying white adipose tissue. Studies in obese primates reported rapid and substantial fat-mass reduction, but also raised safety concerns, including effects on kidney function. It has not been tested in human clinical trials for safety or efficacy, and it is not an approved or clinically validated weight-management therapy. Given its mechanism and unresolved safety signals, it is regarded as a high-risk research compound rather than a viable weight-loss option.
Reported benefits
- Rapid, substantial fat-mass reduction reported in primate studies
- Mechanism distinct from appetite- or incretin-based weight agents
- Has generated research interest in vascular-targeted approaches to fat reduction
How it works
Adipotide is a peptide conjugate that binds to a receptor (prohibitin) found on the blood vessels feeding white adipose tissue and delivers a pro-apoptotic signal, causing programmed cell death of those vessels. Disrupting blood supply to fat tissue is proposed to cause rapid fat-cell death and tissue mass reduction, a mechanism distinct from appetite suppression or metabolic rate changes seen with other weight-related compounds, based on animal research.
Dosing ranges
| Tier | Dose | Frequency |
|---|---|---|
| Low | 0.5 mg | animal-study-derived estimate; not established in humans |
| Moderate | 1 mg | animal-study-derived estimate; not established in humans |
| High | 2 mg | animal-study-derived estimate; not established in humans |
Estimate your dose
Dose estimator
Educational estimate for Adipotide (FTPP), scaled to body size. Not medical advice.
Read before using
This tool produces a rough, educational estimate by scaling commonly-published research ranges to lean body mass. It is not a prescription, medical advice, or a substitute for a licensed clinician. Most peptides use fixed dosing, not weight-based dosing. Individual needs vary. You are solely responsible for how you use this information.
Mixing & syringe units
Target dose follows the estimate above. Change it there, or edit it directly below.
Reconstitution calculator
How much water to add and how many insulin-syringe units to draw for Adipotide (FTPP). Educational only.
Draw to this mark
20units
= 0.2 mL for a 1 mg dose
Concentration
5 mg/mL
Doses per vial
10
A U-100 syringe reads 100 units per mL. This is a reconstitution math helper only, not a prescription or dosing advice. Verify every calculation and consult a qualified healthcare provider.
Possible side effects
Stacking notes
Not established; no controlled data exist on combination with other weight-related compounds, and doing so is not supported by any published research.
Common protocols
Common questions
What is Adipotide (FTPP) used for?
Adipotide, also known as FTPP (Fat-Targeted Proapoptotic Peptide), is an experimental compound studied in animal models for its ability to induce localized apoptosis (programmed cell death) in the blood vessels supplying white adipose tissue. Studies in obese primates reported rapid and substantial fat-mass reduction, but also raised safety concerns, including effects on kidney function. It has not been tested in human clinical trials for safety or efficacy, and it is not an approved or clinically validated weight-management therapy. Given its mechanism and unresolved safety signals, it is regarded as a high-risk research compound rather than a viable weight-loss option. Reported benefits include rapid, substantial fat-mass reduction reported in primate studies, mechanism distinct from appetite- or incretin-based weight agents, has generated research interest in vascular-targeted approaches to fat reduction.
What is a typical Adipotide (FTPP) dose?
Reported ranges run 0.5-2 mg. A low protocol is 0.5 mg animal-study-derived estimate; not established in humans, and a high protocol is 2 mg animal-study-derived estimate; not established in humans. This is reference information, not a dosing recommendation.
What is the half life of Adipotide (FTPP)?
Not established in humans; limited preclinical pharmacokinetic data are available. That is what sets the dosing frequency, and it is why the timing guidance is morning.
How is Adipotide (FTPP) administered?
Subcutaneous: into fat, under the skin. Human clinical dosing has not been established; available data are derived from animal studies only.
How long is a Adipotide (FTPP) cycle?
No established human protocol on, followed by No established human protocol off. All available protocol information derives from primate research and has not been validated for human use.
What are the side effects of Adipotide (FTPP)?
Reported side effects include kidney function changes observed in primate studies, no established human safety data, mechanism (inducing localized cell death) carries theoretical risk of unintended tissue damage, not evaluated for long-term safety in any species. Evidence level for this compound is emerging research.
Partner offer · $20 off
When did you last
check your blood work?
Regular blood work catches changes early. At-home collection with free pickup, 50+ biomarkers, and results in 72 hours.
- 1Order your kitTakes two minutes online, $20 off with this link.
- 2Collect at homePainless draw with free home pickup, no lab visit.
- 3Results in 72 hours50+ biomarkers with clear optimal ranges.
Partner offer · opens rythm.health
Educational use only, not medical advice. This profile is provided for research and educational purposes. Adipotide (FTPP) may be a research compound or a prescription medication; nothing here is intended to diagnose, treat, cure, or prevent any disease. Dosing figures reflect commonly-published research ranges, not a prescription. Consult a qualified healthcare provider before making any health decision. Read the full disclaimer →